Jesse Ledger

Mr. Ledger has been responsible for leading Miravo through its evolution from a manufacturing focused business, to a diversified, global pharmaceutical company. Mr. Ledger joined Miravo in April 2016 as Vice President, Business Development, was appointed President of Miravo in November 2016, and subsequently became President & CEO in November 2017.

Mr. Ledger has over 17 years experience in building product portfolios and pharmaceutical businesses with Canadian, U.S. and international transactional experience. Prior to joining Nuvo, he served as Vice President, Business Development & International Business at Tribute Pharmaceuticals Canada Inc. While at Tribute, Mr. Ledger was a member of the senior management team that completed six transactions with an aggregate value of over CDN$250 million, culminating in a merger with Pozen Inc. and the subsequent formation of Aralez Pharmaceuticals Inc. Prior to joining Tribute, Mr. Ledger was Director, Business Development at SteriMax Inc., a specialty pharmaceutical company focused on the commercialization of essential hospital and retail pharmacy products within Canada, where Mr. Ledger was responsible for a series of successful product acquisition and licensing transactions.

Mr. Ledger holds an honours Bachelor of Business Administration degree from Trent University and is an active member of the Canadian Healthcare Licensing Association (CHLA).